Keyword results: Stuart Ashman

Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast - lied to by Barclays, and fleeced by EasyJet

I discuss both these corporates, and remind the 94% of you yet to support Rogue Bloggers for Woodlarks: please do so, HERE.  Then, I discuss Stuart Ashman of Skinbiotherapitics (SBTX), who has made me look like a complete git (again), as he withdraws from ShareStock. But, I will announce another BIG-name speaker tomorrow, and will replace Stuart. So, make sure you book your tickets, HERE.  Then, I look at Cellular Goods (CBX) and Guild ESports (GILD), the David Beckham dogs. 

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: A night of shame for Mello Events, and Skinbiotherapeutics - I'm buying more

I start with Mello Events, which last night exposed itself as a PR promoter, failing to allow any questions about the elephant in the room: musicMagpie(MMAG).  Then to Optibiotix (OPTI) and Skinbiotherapeutics (SBTX), after today’s news from the latter. I have spoken to both Steve O’Hara and Stuart Ashman. As Les points out in the comments section, the silver lining for you is the postponement of my retirement – but not for long. The market has over-reacted: long-term, these two companies will subsidise the goat farm, as I explain in detail.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bonus Bearcast - why I think Skinbiotherapeutics is a 10 bagger (or more) from here

As you know I am reviewing my pension as discussed HERE. As such I am chatting to various CEOs who I have backed and yesterday evening I had a long chat with Stuart Ashman of Skinbiotherapeutics (SBTX). He is not a bluffing promoter but, I believe, a sober and grounded chap. I came away from the call just incredibly excited. I explain why the share price is where it is but also why this could within a couple of years be a 10 bagger but it could equally be a 20 bagger. Certainly any free cash within my SIPP will, even at twice today’s price be going into this stock. And if I am right there is a clear implication for Optibiotix (OPTI) so I am not selling any shares in it either.  Footnote/correction. There are not 2 million psoriasis sufferers worldwide as per podcast but 120 million. I can’t say that weakens the case!

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Chatting to Stuart Ashman, making a share purchase and meeting a psychic moron

In today’s podcast I discuss why I worry that my wife may have become a real housewife of posh Cheshire, not the part where they play rugby league. Then I look at ADM Energy (ADME) and that RNS reach issue again, tell you about a psychic moron who owns shares in Supply@ME Capital (SYME) and then I discuss, at length, Skinbiotherapeutics (SBTX) after a chat with CEO Stuart Ashman today and on the back of that I have bought more shares in the company.

Subscribe to ShareProphets to access Premium Content
Top-10

Notes from Underground – Most read articles for the week ending 20 November 2021

The top non-Tom article this week is Oil and Gas– I think an inflection point has been reached: oil could hit $200 and here is why by Peter Bailey at number three or number eight if you include the Bearcasts. 

PREMIUM CONTENT

Stuart Ashman, Steve O’Hara, posh PR bird Melanie, and scumbags Cenkos – institutional investors my arse!

As predicted HERE the print going through late on Friday was Optibiotix (OPTI) dumping £2 million worth of Skinbiotherapeutics (SBTX) at 55p. I told you that this would happpen weeks ago producing more bluster and fake denials from all involved. Fuckers! The release this morning insults the intelligence of we loyal shareholders in both companies yet again. Stuart, Steve, posh PR bird Melanie Toyne-Sewell and the scumbags at Cenkos do you think we are idiots? You treat us as if we are.

Subscribe to ShareProphets to access Premium Content
Tom

Tom Winnifrith Video Shareshow No 15: Stuart Ashman runs what could be a 20 bagger and Lucian Miers on his longs and shorts

And now from Wales, by just 30 yards, it is my new weekly video show. This costs 99p per episode, and you can either listen to, or watch, some sparky interviews with Staurt Ashman of Skinbiotherapeutics (SBTX) where I am 130% up in seven months but think the shares could 20 bag from here and bear raider Lucian Miers on macro economics his cooling feelings on cold and warming feelings on bitcoin and his big longs and shorts. Then there are a few thoughts on companies you must NOT own, including the latest nonsense from the scallywags at Powerhouse Energy (PHE).You can access the show HERE

SkinBioTherapeutics – AxisBiotix study enrolment commences, set for a breakthrough year?

Making SkinBioTherapeutics (SBTX) one of our three tips of the year 2021, we noted we considered it likely to make 2021 a breakthrough year, including with a planned first quarter human study for AxisBiotix™ targeting psoriasis and then, subject to a positive readout, commencing commercialisation. Already we now have an Enrolment for AxisBiotix-PsT study commences” announcement and the shares are already massively higher than our 15.5p tip price at 29p. But you’d be mad to sell.

PREMIUM CONTENT

Skinbiotherapeutics placing at 16p – why am I not impressed? But through gritted teeth a buyer

Skinbiotherapeutics (SBTX) boss Stuart Ashman until today held zero shares in the company. And he told us all that it had enough cash to last it until the end of next year at least.  And so now there is a £4 million placing and £500,000 open offer at 16p.  Mr Ashman can you see why I might be annoyed?

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBiotherapeutics: more good news, increased targets upgrade of stance

Very excited shareholder Tom Winnifrith writes: On 26 May 2020, Steve and I tipped SkinBiotherapeutics (SBTX) at a 17.75p offer and at up to 20p with a target price of 30p. News last week suggests that, notwithstanding this company wasting a few grand a month employing the biggest knobhead in Christendom to do its PR, we were more than a tad conservative and the shares now trade at 22p-23.5p and are still dirt cheap.

Subscribe to ShareProphets to access Premium Content

SkinBioTherapeutics – “Business Update”, remains a buy...

SkinBioTherapeutics (SBTX) has updated that it is “very pleased with the progress that the company has been able to make during these most exceptional times”, particularly including “several months ahead of schedule, Winclove has now been able to successfully combine and formulate the blend as a probiotic food supplement, to be known as AxisBiotix ™Ps”...

PREMIUM CONTENT

Skinbiotherapeutics, the most idiotic of PR men and an email exchange

There are only two financial journalists who write regularly about Skinbiotherapeutics (SBTX): myself and Steve Moore. Coverage elsewhere is minimal to zero yet for some reason the company wastes the cash of loyal shareholders such as myself, on Instinctif, a financial PR firm.  Yesterday at 4.16PM on trading statement day Mr Phillip Marriage of Instinctif dropped me an email. I suspect he wishes he had not.  Our full exchange follows.

Subscribe to ShareProphets to access Premium Content
Tom

Tom Winnifrith Shareshow No 4: Well over two and a half hours of David Bramhill of Union Jack, Nigel Somerville on gold and 4 gold stocks to buy & also the red flags at Diversified Gas

And now from Wales, by just 30 yards, it is my new, I hope, weekly show. This costs 99p per episode to access and you can either listen or watch very sparky interviews with our in house gold guru Nigel Somerville on why you must be in gold and on the stocks or ETFs to own to maximise your bull market gains and with Union Jack Oil (UJO) boss David Bramhill, the most underpaid oil CEO on AIM. I also serve up a red flag-spotting session with reference to Diversified Gas & Oil (DGOC). You can access the show HERE

Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|